Novartis's Kymriah wins EU approval for blood cancer treatment

Swiss drugmaker Novartis on Monday received European Commission approval for Kymriah, its CAR-T cell therapy, to treat children with a form of leukemia and adults with lymphoma.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news